Icecure Medical Ltd
ICCM0.950USD
-0.060-5.94%
Market hours （ET）Quotes delayed by 15 min
55.69MMarket Cap
LossP/E TTM
More Details of Icecure Medical Ltd Company
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
Company Info
Ticker SymbolICCM
Company nameIcecure Medical Ltd
IPO dateFeb 02, 2011
CEOMr. Eyal Shamir
Number of employees64
Security typeOrdinary Share
Fiscal year-endFeb 02
Address7 Ha'eshel St.
CityCAESAREA
Stock exchangeNASDAQ Capital Market Consolidated
CountryIsrael
Postal code3079504
Phone97246230333
Websitehttps://icecure-medical.com/
Ticker SymbolICCM
IPO dateFeb 02, 2011
CEOMr. Eyal Shamir
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Eyal Shamir
Mr. Eyal Shamir
Chief Executive Officer, Director
Chief Executive Officer, Director
590.31K
+13.38%
Mr. Ronen Tsimerman
Mr. Ronen Tsimerman
Vice President - Finance, Vice President - Operations
Vice President - Finance, Vice President - Operations
355.08K
+15.46%
Mr. Naum Muchnik
Mr. Naum Muchnik
Vice President - Research & Development
Vice President - Research & Development
140.42K
+33.36%
Mr. Oded Tamir
Mr. Oded Tamir
External Director
External Director
20.00K
+100.00%
Ms. Elisabeth Sadka
Ms. Elisabeth Sadka
Vice President-Clinics, Regulations and Quality Assurance
Vice President-Clinics, Regulations and Quality Assurance
--
--
Ms. Tlalit Bussi Tel-Tzure
Ms. Tlalit Bussi Tel-Tzure
Vice President - Business Development & Marketing
Vice President - Business Development & Marketing
--
--
Ms. Sharon Levita
Ms. Sharon Levita
External Director
External Director
--
--
Mr. Doron Birger
Mr. Doron Birger
Independent Director
Independent Director
--
--
Mr. Yaacov Goldman
Mr. Yaacov Goldman
External Director
External Director
--
--
Mr. Ron Abraham Mayron
Mr. Ron Abraham Mayron
Chairman of the Board
Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Eyal Shamir
Mr. Eyal Shamir
Chief Executive Officer, Director
Chief Executive Officer, Director
590.31K
+13.38%
Mr. Ronen Tsimerman
Mr. Ronen Tsimerman
Vice President - Finance, Vice President - Operations
Vice President - Finance, Vice President - Operations
355.08K
+15.46%
Mr. Naum Muchnik
Mr. Naum Muchnik
Vice President - Research & Development
Vice President - Research & Development
140.42K
+33.36%
Mr. Oded Tamir
Mr. Oded Tamir
External Director
External Director
20.00K
+100.00%
Ms. Elisabeth Sadka
Ms. Elisabeth Sadka
Vice President-Clinics, Regulations and Quality Assurance
Vice President-Clinics, Regulations and Quality Assurance
--
--
Ms. Tlalit Bussi Tel-Tzure
Ms. Tlalit Bussi Tel-Tzure
Vice President - Business Development & Marketing
Vice President - Business Development & Marketing
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
No Data
By RegionUSD
Name
Revenue
Proportion
Other
1.46M
44.24%
United States
870.00K
26.44%
Japan
481.00K
14.62%
India
413.00K
12.55%
China
41.00K
1.25%
Israel
30.00K
0.91%
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Jul 27
Updated: Sun, Jul 27
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Haixiang (Li)
44.03%
Shamir (Eyal)
1.01%
Tsimerman (Ronen)
0.60%
Mayron (Ron)
0.47%
Tel-Tzure (Tlalit Bussi)
0.33%
Other
53.55%
Shareholders
Shareholders
Proportion
Haixiang (Li)
44.03%
Shamir (Eyal)
1.01%
Tsimerman (Ronen)
0.60%
Mayron (Ron)
0.47%
Tel-Tzure (Tlalit Bussi)
0.33%
Other
53.55%
Shareholder Types
Shareholders
Proportion
Individual Investor
47.49%
Investment Advisor
0.12%
Investment Advisor/Hedge Fund
0.09%
Venture Capital
0.04%
Research Firm
0.03%
Other
52.24%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
45
28.04M
47.77%
+71.20K
2025Q1
44
28.01M
47.78%
-9.18K
2024Q4
41
27.61M
48.82%
+489.62K
2024Q3
42
27.95M
49.54%
-2.17M
2024Q2
41
27.48M
56.81%
+3.00M
2024Q1
39
27.22M
56.29%
+2.63M
2023Q4
40
21.73M
47.63%
-6.82M
2023Q3
37
21.68M
47.52%
-6.84M
2023Q2
36
21.65M
47.45%
-6.97M
2023Q1
32
21.72M
47.62%
-6.97M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Haixiang (Li)
25.85M
44.09%
--
--
Dec 31, 2024
Shamir (Eyal)
590.31K
1.01%
+69.67K
+13.38%
Mar 24, 2025
Tsimerman (Ronen)
355.08K
0.61%
+47.55K
+15.46%
Mar 24, 2025
Mayron (Ron)
278.02K
0.47%
+55.45K
+24.91%
Mar 24, 2025
Tel-Tzure (Tlalit Bussi)
191.81K
0.33%
+35.32K
+22.57%
Mar 24, 2025
Levav (Shay)
141.86K
0.24%
+37.69K
+36.18%
Mar 24, 2025
Muchnik (Naum)
140.42K
0.24%
+35.13K
+33.36%
Mar 24, 2025
Huang (Yang)
113.44K
0.19%
+40.12K
+54.72%
Mar 24, 2025
Dotan (Merav Nir)
88.94K
0.15%
+30.84K
+53.09%
Mar 24, 2025
Malik (Galit)
79.67K
0.14%
+23.32K
+41.40%
Mar 24, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
